2024年ESMO会议揭示了艾沃内斯基马布在第一线转移性结直肠癌治疗中的有希望的疗效数据;这种组合优于标准治疗,安全性可控. 2024 ESMO Conference reveals promising efficacy data for ivonescimab in first-line metastatic colorectal cancer treatment; combination superior to standard treatments with manageable safety.

Akeso在2024年无害环境管理组织会议上展示了其PD-1/VEGF双专门抗体(ivonescimab)的有希望的功效数据。 Akeso revealed promising efficacy data for its PD-1/VEGF bispecific antibody, ivonescimab, at the 2024 ESMO Conference. 这些发现表明,单独使用和与ligufalimab和FOLFOXIRI联合使用的IVONESCIMAB具有强大的抗瘤活性,用于转移性结直肠癌 (MSS/ pMMR) 的第一线治疗. The findings indicate that ivonescimab, both alone and with ligufalimab and FOLFOXIRI, exhibits strong anti-tumor activity for first-line treatment of metastatic colorectal cancer (MSS/pMMR). 与标准处理方法相比,结合结果显示效果优于标准处理方法,安全情况可管理,有助于进一步研究。 The combination showed superior efficacy compared to standard treatments, with manageable safety profiles, supporting further research.